Drug intelligence / Profile preview

PD-DP-RDC

Development stage: Preclinical
Lead developer: Chengdu Peide Biopharmaceutical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PD-DP-RDC is a preclinical-stage radionuclide drug conjugate (RDC) being developed by Chengdu Peide Biopharmaceutical for the treatment of cancer. As an RDC, the therapeutic candidate is designed to deliver targeted radiation directly to tumor cells by conjugating a radioactive isotope to a targeting ligand, such as a peptide or small molecule. The program is currently in the lead optimization or preclinical phase of development. Specific details regarding the molecular target and the radionuclide payload have not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on PD-DP-RDC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-DP-RDC.

Explore the full profile